General Information of Synthetic Binding Protein (SBP) (ID: SBP003370)
SBP Name
scFv anti-VEGF-A Brolucizumab
Synonyms
scFv Brolucizumab
Molecular Weight 26.3 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Research
Sequence Length 252
SBP Sequence
>scFv anti-VEGF-A Brolucizumab
MEIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVP
SRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVLGGGGGSGGG
GSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEW
VGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLD
IWGQGTLVTVSS
3D Structure
Computationally Modelled Structure
Click to Save PDB File
Protein Scaffold Information of This SBP
Scaffold ID PS057
Scaffold Info
[1]
Scaffold Name scFv
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Vascular endothelial growth factor A
BTS Info
Binder Diabetic macular oedema [ICD-11: 9B71.02]; Retinal vein occlusion [ICD-11: 9B74.1]; Diabetic retinopathy [ICD-11: 9B71.0Z] N.A. Mairangi Bay [1]
References
1 Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.